Europe Healthcare Cold Chain Logistics Market: Market Size & Forecast 2026

Healthcare cold chain logistics in Europe covers the end-to-end supply chain management of temperature-critical medical products, ranging from frozen (-70°C) to refrigerated (2-8°C) and controlled room temperature (15-25°C) environments. The market encompasses transportation by road, air, and sea; specialized warehousing; and value-added services such as real-time temperature monitoring, regulatory compliance management, and last-mile delivery to hospitals and pharmacies. Regulatory frameworks including EU GDP guidelines and national medicines agencies mandate rigorous quality controls, making specialized logistics providers essential to the pharmaceutical and biotech supply chain.

• •The market was valued at approximately $11.41 billion in 2025 and is projected to grow at 9.69% annually, reaching roughly $18-19 billion by the end of the decade
• •Key temperature segments include deep freeze (-70°C to -20°C), refrigerated (2-8°C), and controlled room temperature (15-25°C), with refrigerated logistics representing the largest share
• •The market serves pharmaceuticals, biologics, vaccines, clinical trial materials, and emerging cell and gene therapy products

The shift toward biologic drugs and biosimilars is a primary catalyst, as these protein-based therapies require uninterrupted cold chain integrity, a challenge that smaller molecule conventional drugs do not pose to the same degree. The aftereffects of the COVID-19 pandemic, including expanded vaccine manufacturing capacity and ongoing immunization programs, have led pharmaceutical companies and governments to invest heavily in cold chain infrastructure. Additionally, the rising prevalence of chronic diseases and an aging European population are increasing demand for specialty pharmaceuticals that demand sophisticated temperature-controlled logistics.

• •Biologics and biosimilars now represent over 40% of the pharmaceutical pipeline, driving outsized demand for refrigerated and frozen logistics services compared to traditional drugs
• •Cell and gene therapy products, often requiring -70°C cryogenic logistics, are entering clinical and commercial stages, creating a fast-growing ultra-cold logistics sub-segment
• •EU regulatory requirements under Good Distribution Practice and upcoming traceability mandates under the Falsified Medicines Directive are compelling manufacturers to upgrade cold chain capabilities

By service type, the market is segmented into transportation (the largest segment), warehousing, and packaging, with value-added services such as customs clearance, regulatory compliance, and real-time monitoring bundled increasingly by leading providers. Temperature-wise, the market divides into frozen, refrigerated, and controlled room temperature segments, with refrigerated logistics holding the dominant share. Geographically, Western Europe accounts for the largest market share, led by Germany as a pharmaceutical manufacturing hub, followed by France and the United Kingdom.

• •Germany is the largest national market, home to major pharma manufacturing clusters and a dense network of GDP-certified logistics providers, followed by France and the UK
• •Northern Europe, including the Benelux countries and Scandinavia, holds significant share due to strong pharmaceutical R&D activity and stringent regulatory enforcement
• •Eastern Europe is the fastest-growing regional segment as pharmaceutical manufacturing and clinical trial activity increasingly relocate to lower-cost EU member states

What are the recent trends and outlook?

The integration of IoT-based real-time temperature monitoring and blockchain-enabled traceability is reshaping how shippers manage cold chain visibility, with providers investing in digital platforms that offer predictive alerting and regulatory-compliant documentation. Sustainability pressures are also influencing the market, with logistics providers increasingly deploying electric refrigerated vehicles, carbon-neutral warehousing, and reusable insulated packaging to meet both corporate and regulatory sustainability targets. Over the forecast horizon through 2030, the market is expected to see consolidation among mid-tier regional providers and continued innovation in ultra-cold logistics to support the commercialization of mRNA-based and cell therapies.

• •Real-time monitoring and digital cold chain platforms are becoming standard offerings, with providers adopting IoT sensors, GPS tracking, and cloud-based data management to meet regulatory and shipper demands for end-to-end visibility
• •The cell and gene therapy logistics segment, including CAR-T treatments and mRNA therapeutics, is expected to outpace overall market growth, driving investment in cryogenic and portable cold chain solutions
• •Sustainability initiatives are accelerating, with logistics providers investing in green refrigerants, recyclable insulated packaging, and carbon-neutral delivery routes to align with EU Green Deal objectives